BacMam-Enabled LanthaScreen® Cellular Assays for PI3K/Akt Pathway Compound Profiling in Disease-Relevant Cell Backgrounds

The authors recently reported the development and application of multiple LanthaScreen® cellular assays to interrogate specific steps within the PI3K/Akt pathway. The importance of this signaling cascade in regulating fundamental aspects of cell growth and survival, as well as in the progression of cancer, underscores the need for portable cell-based assays for compound profiling in multiple disease-relevant cell backgrounds. To meet this need, the authors have now expanded their LanthaScreen® assay platform across a variety of cell types using a gene delivery technology known as BacMam. Here, they have demonstrated the successful detection of Akt-dependent phosphorylation of PRAS40 at Thr246 in 10 different cell lines harboring mutations known to activate the PI3K/Akt pathway. In addition, they generated inhibitory profiles of 17 known pathway inhibitors in these same cells to validate the approach of using the BacMam-enabled LanthaScreen® cellular assay format to rapidly profile compounds in disease-relevant cell types. Importantly, their results provide a broad illustration of how the genetic alterations that affect PI3K/Akt signaling can also influence the inhibitory profile of a given compound.

• Publication year

  2010

• Venue

  Journal of biomolecular screening

• Publication date

  2010-02-09

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1177/1087057109357788PMID 20145103
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Development of LanthaScreen™ Cellular Assays for Key Components within the PI3K/AKT/mTOR Pathway

  2009cited by this paper
• Characterization of serotonin 5-hydroxytryptamine-1A receptor activation using a phospho-extracellular-signal regulated kinase 2 sensor.

  2009cited by this paper
• PRAS40: Target or modulator of mTORC1 signalling and insulin action?

  2009cited by this paper
• High-throughput cellular assays for regulated posttranslational modifications.

  2008cited by this paper
• Cellular LanthaScreen and β-Lactamase Reporter Assays for High-Throughput Screening of JAK2 Inhibitors

  2008cited by this paper
• Breast Tumor Cells with PI3K Mutation or HER2 Amplification Are Selectively Addicted to Akt Signaling

  2008cited by this paper
• Drug discovery approaches targeting the PI3K/Akt pathway in cancer

  2008cited by this paper
• A chemical screen in diverse breast cancer cell lines reveals genetic enhancers and suppressors of sensitivity to PI3K isoform-selective inhibition.

  2008cited by this paper
• Evidence for functional redundancy of class IA PI3K isoforms in insulin signalling.

  2007cited by this paper
• Implementation of BacMam virus gene delivery technology in a drug discovery setting.

  2007cited by this paper
• BacMam technology and its application to drug discovery

  2007cited by this paper
• Targeting the AKT protein kinase for cancer chemoprevention

  2007cited by this paper
• Handicapping the Race to Develop Inhibitors of the Phosphoinositide 3-Kinase/Akt/Mammalian Target of Rapamycin Pathway

  2006cited by this paper
• Blockade of PI3Kgamma suppresses joint inflammation and damage in mouse models of rheumatoid arthritis.

  2005cited by this paper
• Potent and selective inhibitors of Akt kinases slow the progress of tumors in vivo

  2005cited by this paper
• The Akt inhibitor KP372-1 suppresses Akt activity and cell proliferation and induces apoptosis in thyroid cancer cells

  2005cited by this paper
• Blockade of PI3Kγ suppresses joint inflammation and damage in mouse models of rheumatoid arthritis

  2005cited by this paper
• Exploiting the PI3K/AKT Pathway for Cancer Drug Discovery

  2005cited by this paper
• Transient and stable gene expression in mammalian cells transduced with a recombinant baculovirus vector.

  1999cited by this paper
• Up-regulation of Akt3 in Estrogen Receptor-deficient Breast Cancers and Androgen-independent Prostate Cancer Lines*

  1999cited by this paper

• Selective therapeutic benefit of X-rays and inhibitors of EGFR, PI3K/mTOR, and Bcl-2 in breast, lung, and cervical cancer cells.

  2021cites this paper
• Energy transfer in liquid and solid nanoobjects: application in luminescent analysis

  2018cites this paper
• Strong synergism between small molecule inhibitors of HER2, PI3K, mTOR and Bcl-2 in human breast cancer cells.

  2017cites this paper
• Assays with Detection of Fluorescence Anisotropy: Challenges and Possibilities for Characterizing Ligand Binding to GPCRs.

  2017cites this paper
• Evaluation of small molecule inhibitors of HER2, PI3K, mTOR and Bcl-2 for their radiomodulatory effects in human breast cancer cell lines

  2016cites this paper
• Radiosensitisation of low HER-2 expressing human breast cancer cell lines

  2015cites this paper
• Genetically Encoded FRET-Sensor Based on Terbium Chelate and Red Fluorescent Protein for Detection of Caspase-3 Activity

  2015cites this paper
• A Cocktail of Specific Inhibitors of HER-2, PI3K, and mTOR Radiosensitises Human Breast Cancer Cells

  2015influential citation
• Discovery of a Potent, Covalent BTK Inhibitor for B-Cell Lymphoma

  2014cites this paper
• Using lanthanide-based resonance energy transfer for in vitro and in vivo studies of biological processes

  2012cites this paper
• Role of PRAS40 in Akt and mTOR signaling in health and disease.

  2012cites this paper
• Role of PRAS 40 in Akt and mTOR signaling in health and disease

  2012cites this paper
• Functional characterization of an isoform-selective inhibitor of PI3K-p110β as a potential anticancer agent.

  2012cites this paper
• Screening and Drug Discovery

  2011cites this paper
• Establishing assays and small molecule screening facilities for Drug discovery programs

  2011cites this paper